ROBERT STEVEN SIEGEL M.D.
Prescription History 1003985367
Internal Medicine - Hematology & Oncology in Washington, DC

NPI Status: Active since November 08, 2006

Contact Information

2150 PENNSYLVANIA AVE NW
WASHINGTON, DC
ZIP 20037
Phone: (202) 741-3333
Fax: (202) 741-3396

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ROBERT STEVEN SIEGEL M.D., an active Hematology & Oncology specialist practicing in Washington, DC. Our medical registry currently tracks 17 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 476 documented patient claims. Among these therapy options, the most frequently utilized medication is Xtandi, which accounts for 101 claims alone.


Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 51
30-Day Fills 61.0
Days Supply 1,830
DC State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills66.1
Peer Average Days Supply1,982
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $217,188.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,258.59

State Avg Cost Per Claim

$2,752.25

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 39.0
Days Supply 1,170
DC State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills38.3
Peer Average Days Supply1,038
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $417.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.90

State Avg Cost Per Claim

$25.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.0
Days Supply 990
DC State Average Benchmarks
Peer Average Claims63.0
Peer Average 30-Day Fills149.7
Peer Average Days Supply4,485
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.0% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $975.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$57.40

State Avg Cost Per Claim

$27.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 62.9
Days Supply 1,798
DC State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply514
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 48.0% more claims than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $666.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.02

State Avg Cost Per Claim

$21.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 25.5
Days Supply 765
DC State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills72.6
Peer Average Days Supply2,095
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.0% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $181.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$10.68

State Avg Cost Per Claim

$22.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Gammaked

Generic Formulation: Immune Globul G/Gly/Iga Avg 46Specialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
DC State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $87,631.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$7,302.65

State Avg Cost Per Claim

$6,684.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used in people with a certain type of weakened immune system (primary immune deficiency) to strengthen it and to lower the risk of infection. This medication is made from human blood that has a high level of antibodies which help fight infections. This product is also used to increase the number of certain blood cells (platelets) in people with a certain blood disorder (idiopathic thrombocytopenic purpura-ITP). Platelets are needed to stop bleeding and to form normal blood clots. In addition, this medication is used to treat a certain nerve disorder (chronic inflammatory demyelinating polyneuropathy-CIDP). This disorder causes weakness and numbness/tingling/pain in the arms and legs. This medication helps to improve these symptoms and prevents relapse.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
DC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.9
Peer Average Days Supply657
Conservative Utilization

This provider writes prescriptions for this formulation 45.0% less frequently than the standard regional baseline metric for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $38,083.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,462.12

State Avg Cost Per Claim

$5,834.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 978
DC State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.1
Peer Average Days Supply599
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 70.0% higher than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $478,673.95 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,078.65

State Avg Cost Per Claim

$15,788.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.0
Days Supply 990
DC State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills95.3
Peer Average Days Supply2,854
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 72.5% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $661.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$60.18

State Avg Cost Per Claim

$30.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 336
DC State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.5
Peer Average Days Supply462
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $158,131.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,177.61

State Avg Cost Per Claim

$12,538.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 130
DC State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.5
Peer Average Days Supply273
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $98.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.19

State Avg Cost Per Claim

$18.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Orgovyx

Generic Formulation: RelugolixSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
DC State Average Benchmarks
Peer Average Claims62.0
Peer Average 30-Day Fills65.4
Peer Average Days Supply1,937
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.9% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $61,828.50 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,688.20

State Avg Cost Per Claim

$2,682.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Relugolix is used to treat prostate cancer in men. It is not a cure. Most types of prostate cancer need the male hormone testosterone to grow and spread. Relugolix works by reducing the amount of testosterone that the body makes. This helps slow or stop the growth of cancer cells.

Prednisone

Generic Formulation: PrednisoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 43
30-Day Fills 61.3
Days Supply 1,790
DC State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills42.2
Peer Average Days Supply926
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.4% more claims than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $345.58 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.04

State Avg Cost Per Claim

$7.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
DC State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills42.3
Peer Average Days Supply1,163
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.9% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $295,688.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,480.51

State Avg Cost Per Claim

$18,707.62

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 30
30-Day Fills 82.0
Days Supply 2,460
DC State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills43.3
Peer Average Days Supply1,298
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.9% higher than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,446.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.23

State Avg Cost Per Claim

$33.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 28
30-Day Fills 44.0
Days Supply 1,296
DC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills61.1
Peer Average Days Supply1,698
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $27,188.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$971.02

State Avg Cost Per Claim

$924.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Xtandi

Generic Formulation: EnzalutamideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 101
30-Day Fills 101.0
Days Supply 3,030
DC State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills39.6
Peer Average Days Supply1,186
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 159.0% higher than the standard regional baseline profile for DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,293,105.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,803.02

State Avg Cost Per Claim

$13,236.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enzalutamide is used to treat prostate cancer. This medication belongs to a class of drugs known as anti-androgens (anti-testosterone). It works by blocking the effects of testosterone to slow the growth and spread of prostate cancer.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ROBERT STEVEN SIEGEL M.D. provides transparency into local medical care patterns within Washington, DC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.